Business Wire

Moody’s Provides $1 Million in Funding for COVID-19 Relief

Share

Moody’s Corporation (NYSE: MCO) today announced that it will fund a $1 million program of charitable donations and other support to help address the immediate and long-term impact of COVID-19. Moody’s will extend support to its existing philanthropic partners to help small businesses and education systems and reconfigure its employee volunteer programs to assist communities most affected by the pandemic.

“COVID-19 has caused unprecedented disruption to the health and economic security of people around the world,” said Raymond McDaniel, President and CEO of Moody’s Corporation. “Moody’s Corporation and our employees are committed to assisting organizations that are providing vital relief and recovery work in local communities during this difficult time.”

To help with urgent needs, Moody’s will provide $550,000 of funding for humanitarian aid to support global efforts to alleviate food insecurity, bolster healthcare systems, purchase medical supplies, and support research focused on containment and treatment. Funds will also be distributed to organizations involved in direct relief work in communities where Moody’s operates, including:

This funding builds on Moody’s $50,000 donation to Give2Asia in January, which helped provide health care workers with training and medical equipment to contain the spread of COVID-19 in China.

Moody’s will also increase support for its existing CSR program partners by pledging an additional $450,000 in unrestricted grants to address the impact of COVID-19 on small businesses and education systems. The company will also provide partners with pro bono resources to bolster their operations and support their transition to virtual programs.

In addition, Moody’s will be instituting a virtual employee volunteer program and reconfiguring its Moody’s Future Solutions™ program to allow employees to continue their community engagements while adhering to social distancing guidelines. The company also will match eligible employee donations to nonprofits responding to COVID-19 via its Matching Gifts Program.

ABOUT MOODY’S CORPORATION

Moody’s (NYSE:MCO) is a global integrated risk assessment firm that empowers organizations to make better decisions. Our data, analytical solutions and insights help decision-makers identify opportunities and manage the risks of doing business with others. We believe that greater transparency, more informed decisions, and fair access to information open the door to shared progress. With over 11,000 employees in more than 40 countries, Moody’s combines international presence with local expertise and over a century of experience in financial markets. Learn more at moodys.com/about.

Moody’s builds toward a world where more people have access to opportunity, and where everyone has what they need to grow and thrive. We are committed to opening the door to brighter futures through our global corporate social responsibility programs connecting people around the world with the knowledge and resources they need to succeed. For more information visit moodys.com/csr.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

SHIVANI KAK
Investor Relations
212.553.0298
shivani.kak@moodys.com

JORDAN BRUECKNER
Communications
+1 212-553-7931
jordan.brueckner@moodys.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 202517.9.2025 08:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will support the planned regulatory submissions for povorcitinib in HS in Europe and the United States in 2025 and early 2026, respectively. The presentation will take place today at 2:45 p.m. CEST during a late-breaking oral presentation (Session: Late Breaking News; Presentation ID D1T01.1C) at the European Association of Dermatology and Venereology (EADV) 2025 Congress. “HS remains a challenging and often debilitating condition and many patients are in need of new, well-tolerated and effective therapies that address prominent signs and symptoms of the disease, including inflammatory lesions and pain,” said Pablo J. Cagnoni, M.D., President and Head of Res

Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin17.9.2025 08:00:00 EEST | Press release

Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental factors on individuals with sensitive skin.1 Results from the study, conducted by dermatology experts from Galderma’s Global Sensitive Skincare Faculty (GSSF), will be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress on Friday, September 19. The findings provide compelling evidence that modern, urban lifestyles are associated with worsened skin health in people with sensitive skin.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916245806/en/ Sensitive skin affects up to 70% of people globally – a figure that has risen by 68% over the past two decades – yet it remains widely overlooked and under-studied.2,3 As more people live fast-paced lives in densely populated urban cities, growing evidence

Overture Life Launches European Preorder Waitlist for DaVitri, the World’s First Microfluidics-Based Automated Vitrification Platform17.9.2025 08:00:00 EEST | Press release

Overture Life, the innovator modernizing IVF to optimize reproductive freedom, today announced the launch of its European preorder waitlist for DaVitri, the world’s first automated vitrification platform. The waitlist ensures in vitro fertilization (IVF) facilities will be among the first in Europe to harness DaVitri to reduce manual workloads for their embryologists while eliminating operator variability, thereby providing patients with faster, more consistent procedures. As infertility rates spike worldwide, interest in egg freezing continues to rise while the infrastructure to support it lags behind. Egg freezing requires vitrification, typically a time-intensive, manual process vulnerable to human error that can only be performed by extensively trained embryologists. This has resulted in variability in egg and embryo survival rates that directly impact IVF success, as well as significant access issues caused by the throughput bottleneck. DaVitri automates egg vitrification, deliver

Ant International Recognized as an Inaugural Foreign Institution Partner by China’s Cross-Border Interconnection Payment Gateway17.9.2025 07:24:00 EEST | Press release

Ant International is appointed as an inaugural foreign Institution Partner (FIP) of China’s Cross-border Interconnection Payment Gateway (CPG), under the guidance of the People’s Bank of China and the Payment & Clearing Association of China (PCAC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916704996/en/ Eric Jing, Chairman of Ant Group and Ant International, and Cyril Han, CEO of Ant Group, celebrating China's Top International consumer destinations with card and wallet partners. Ant International and Alipay are the largest player in the CPG scheme with the largest number of card network and wallet partners, the broadest use cases and largest business volume. The new CPG scheme is designed to raise connection efficiency and improve system stability for overseas payment partners. Its timely launch opens a safe and smoother highway for these partners to access the Chinese market. Alipay+, the cross-border payment and d

Ant International Joins Google's Agent Payments Protocol as a Launch Partner17.9.2025 07:00:00 EEST | Press release

Ant International, a leading global provider of digital payments, digitisation, and financial technology, today announced its role as a launch partner of Google to develop Agent Payments Protocol (AP2), an open rulebook that defines how AI agents can reliably transact with the authorisation of users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916339888/en/ With the rise of agentic commerce, AI agents will increasingly transact on behalf of users for services, products, and even other agents. Existing payment systems are built around direct human interaction and cannot currently address the new requirements of authorization, verification, and interoperability among agents. To address this gap, Google has collaborated with the industry to introduce AP2. AP2 defines the key components of agentic payments and provides a protocol to ensure user intent is verifiable, transactions are traceable, and accountability is clear f

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye